Eunice L Kwak Selected Research

folfirinox

7/2019	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
1/2018	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
1/2018	Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
1/2015	Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
1/2013	FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eunice L Kwak Research Topics

Disease

48	Neoplasms (Cancer) 01/2024 - 05/2005
15	Adenocarcinoma 07/2019 - 07/2006
13	Pancreatic Neoplasms (Pancreatic Cancer) 07/2019 - 07/2006
8	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 01/2012
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 10/2010
5	Neoplasm Metastasis (Metastasis) 01/2017 - 12/2007
5	Lung Neoplasms (Lung Cancer) 01/2014 - 05/2005
4	Cholangiocarcinoma 02/2016 - 01/2012
3	Fatigue 01/2020 - 06/2009
3	Fibrosis (Cirrhosis) 01/2017 - 01/2014
3	Hepatocellular Carcinoma (Hepatoma) 02/2016 - 06/2009
3	Stomach Neoplasms (Stomach Cancer) 01/2016 - 10/2014
3	Disease Progression 12/2015 - 01/2012
3	Neutropenia 10/2012 - 06/2009
2	Melanoma (Melanoma, Malignant) 01/2024 - 12/2015
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2019 - 01/2012
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 04/2017 - 01/2012
2	Carcinogenesis 04/2015 - 02/2006
2	Hyperglycemia 01/2015 - 11/2011
2	Breast Neoplasms (Breast Cancer) 01/2014 - 02/2006
2	Esophageal Neoplasms (Esophageal Cancer) 01/2013 - 01/2013
2	Lymphopenia (Lymphocytopenia) 10/2012 - 11/2011
2	Ovarian Neoplasms (Ovarian Cancer) 02/2011 - 07/2005
1	Mesothelioma 01/2024
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2024
1	Triple Negative Breast Neoplasms 01/2024
1	Microsatellite Instability 01/2016
1	Giant Cell Tumor of Tendon Sheath 07/2015
1	Giant Cell Tumors (Giant Cell Tumor) 07/2015
1	Stomatitis 01/2015
1	Inflammation (Inflammations) 01/2015
1	Nausea 01/2015
1	Pancreatic Fistula (Pancreatic Fistulas) 01/2015
1	Vomiting 01/2015

Drug/Important Bio-Agent (IBA)

9	CrizotinibIBA 01/2020 - 10/2010
6	Capecitabine (Xeloda)FDA Link 07/2019 - 07/2006
6	Biomarkers (Surrogate Marker)IBA 01/2016 - 12/2007
6	ErbB Receptors (EGF Receptor)IBA 01/2014 - 05/2005
5	folfirinoxIBA 07/2019 - 01/2013
5	Irinotecan (Camptosar)FDA LinkGeneric 07/2019 - 01/2012
4	Alanine Transaminase (SGPT)IBA 01/2020 - 01/2010
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2019 - 01/2010
4	Protons (Proton)IBA 07/2019 - 01/2014
4	Cetuximab (Erbitux)FDA Link 02/2016 - 01/2012
4	Proteins (Proteins, Gene)FDA Link 01/2016 - 07/2005
3	Fluorouracil (Carac)FDA LinkGeneric 07/2019 - 01/2013
3	Gemcitabine FDA Link 01/2018 - 10/2007
3	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 09/2015 - 01/2012
3	Phosphotransferases (Kinase)IBA 07/2015 - 05/2005
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2015 - 01/2013
3	Tyrosine Kinase InhibitorsIBA 01/2014 - 05/2005
3	Anaplastic Lymphoma KinaseIBA 01/2013 - 10/2010
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2007 - 05/2005
2	spartalizumabIBA 01/2024 - 01/2022
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 10/2020 - 01/2013
2	Leucovorin (Folinic Acid)FDA Link 07/2019 - 01/2013
2	Cell-Free Nucleic AcidsIBA 01/2019 - 01/2018
2	Protein Isoforms (Isoforms)IBA 09/2017 - 01/2015
2	Messenger RNA (mRNA)IBA 01/2016 - 06/2008
2	temsirolimus FDA Link 01/2014 - 09/2008
2	TOR Serine-Threonine KinasesIBA 01/2014 - 11/2011
2	neratinibIBA 01/2014 - 05/2005
2	human ERBB2 proteinIBA 08/2013 - 01/2013
2	Everolimus FDA Link 01/2013 - 11/2011
2	Gefitinib (Iressa)FDA Link 07/2006 - 05/2005
1	STA 9090IBA 10/2020
1	Losartan (Cozaar)FDA LinkGeneric 07/2019
1	AMG 337IBA 04/2019
1	130-nm albumin-bound paclitaxelIBA 01/2018
1	serabelisibIBA 09/2017
1	N-acetyltalosaminuronic acid (NAT)IBA 04/2016
1	Cytidine Triphosphate (CTP)IBA 02/2016
1	Cadherins (E-Cadherin)IBA 01/2016
1	dabrafenibIBA 12/2015
1	Mitogen-Activated Protein KinasesIBA 12/2015
1	Circulating Tumor DNAIBA 12/2015
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2015
1	trametinibIBA 12/2015
1	Macrophage Colony-Stimulating FactorIBA 07/2015
1	pexidartinibIBA 07/2015
1	cabozantinibIBA 04/2015
1	IMO-2055IBA 04/2015
1	gedatolisibIBA 01/2015
1	LactonesIBA 06/2014
1	CamptothecinIBA 06/2014
1	TLC 388IBA 06/2014
1	alpha-hydroxyglutarateIBA 04/2014

Therapy/Procedure

22	Therapeutics 01/2024 - 10/2007
9	Neoadjuvant Therapy 07/2019 - 06/2012
9	Radiotherapy 01/2018 - 01/2012
8	Drug Therapy (Chemotherapy) 07/2019 - 09/2007
3	Chemoradiotherapy 07/2019 - 01/2018
3	Proton Therapy 02/2016 - 01/2011
2	Adjuvant Chemotherapy 01/2018 - 03/2014
2	Operative Surgical Procedures 11/2016 - 04/2016
2	Lymph Node Excision (Lymph Node Dissection) 04/2016 - 01/2016
2	Gastrectomy 01/2016 - 10/2013
1	Splenectomy 04/2016
1	Operative Time 01/2015
1	Pancreaticoduodenectomy 07/2014